ZLAB Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

19.440

Open

19.190

VWAP

19.22

Vol

606.07K

Mkt Cap

2.17B

Low

18.870

Amount

11.65M

EV/EBITDA(TTM)

--

Total Shares

112.35M

EV

1.72B

EV/OCF(TTM)

--

P/S(TTM)

4.63

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

Show More

Events Timeline

(ET)

2026-06-16

07:30:00

Zai Lab Receives EMA Orphan Drug Designation for New Drug

2026-05-21 (ET)

2026-05-21

18:30:00

Zai Lab Announces Leadership Changes to Enhance Operational Efficiency

2026-05-11 (ET)

2026-05-11

07:20:00

Zai Lab's zocilurtatug Receives FDA Fast Track Designation

2026-05-07 (ET)

2026-05-07

06:40:00

Company Reports Q1 Revenue of $99.6M, Below Expectations

2026-04-19 (ET)

2026-04-19

13:10:00

Zai Lab's ZL-1503 Shows Significant Efficacy in Preclinical Study

2026-04-17 (ET)

2026-04-17

15:10:00

Zai Lab's Zocilurtatug Pelitecan Shows Promising Efficacy in Small Cell Lung Cancer Patients

2026-04-01 (ET)

2026-04-01

07:40:00

Zai Lab Collaborates with Amgen on Clinical Trial for zocilurtatug

News

CNBC

Tech Stocks Decline as OpenAI IPO Plans Face Challenges

CNBC

Anthropic's Suspension of AI Models Sparks Market Concerns

seekingalpha

06-09seekingalpha

Zai Lab's Tivdak Approved in China for Cervical Cancer Treatment

Newsfilter

06-09Newsfilter

TIVDAK Approved in China for Cervical Cancer Treatment

CNBC

Analysts Favor Investment in China's AI Stocks

seekingalpha

05-22seekingalpha

Zai Lab Leadership Change to Enhance Efficiency

5 Analyst Rating

Wall Street analysts forecast ZLAB stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.70

Averages

47.93

High

74.00

Current: 0.000

Low

25.70

Averages

47.93

High

74.00

Citi

Buy

to

Buy

downgrade

$47 -> $44

AI Analysis

2026-05-08

Reason

Citi

Price Target

$47 -> $44

AI Analysis

2026-05-08

downgrade

Buy

to

Buy

Reason

Citi lowered the firm's price target on Zai Lab to $44 from $47 and keeps a Buy rating on the shares. The firm updated the company's model post the Q1 report.

JPMorgan

Anupam Rama

Overweight

downgrade

$39 -> $32

2026-03-18

Reason

JPMorgan

Anupam Rama

Price Target

$39 -> $32

2026-03-18

downgrade

Overweight

Reason

JPMorgan analyst Anupam Rama lowered the firm's price target on Zai Lab to $32 from $39 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology space.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZLAB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Zai Lab Ltd (ZLAB.O) is 0.00, compared to its 5-year average forward P/E of -16.99. For a more detailed relative valuation and DCF analysis to assess Zai Lab Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-16.99

Current PE

0.00

Overvalued PE

4.27

Undervalued PE

-38.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-12.52

Current EV/EBITDA

-4.34

Overvalued EV/EBITDA

1.07

Undervalued EV/EBITDA

-26.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

11.98

Current PS

3.61

Overvalued PS

25.52

Undervalued PS

-1.56

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stock should I trade today

Intellectia · 19 candidates

Market Cap: >= 1000.00MPrice: $5.00 - $100.00Price Change Pct: >= $3.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Polestar Automotive Holding UK PLC

1.21B

FormFactor Inc

5.43B

AXT Inc

1.11B

Ocular Therapeutix Inc

1.80B

Blue Bird Corp

1.58B

Kulicke and Soffa Industries Inc

2.89B

Whales Holding ZLAB

Frazier Life Sciences Management, LP

ADAR1 Capital Management, LLC

Maxwealth Fund Management Co., Ltd

Trading Trends

People Also Watch

Frequently Asked Questions

What is Zai Lab Ltd (ZLAB) stock price today?

The current price of ZLAB is 19.35 USD — it has increased 1.42

What is Zai Lab Ltd (ZLAB)'s business?

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

What is the price predicton of ZLAB Stock?

Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is47.93 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Zai Lab Ltd (ZLAB)'s revenue for the last quarter?

Zai Lab Ltd revenue for the last quarter amounts to 99.61M USD, decreased -6.46

What is Zai Lab Ltd (ZLAB)'s earnings per share (EPS) for the last quarter?

Zai Lab Ltd. EPS for the last quarter amounts to -0.05 USD, increased 25.00

How many employees does Zai Lab Ltd (ZLAB). have?

Zai Lab Ltd (ZLAB) has 1784 emplpoyees as of July 08 2026.

What is Zai Lab Ltd (ZLAB) market cap?

Today ZLAB has the market capitalization of 2.17B USD.